PRGO:NYE-Perrigo Company plc (USD)

EQUITY | Drug Manufacturers - Specialty & Generic | New York Stock Exchange

Last Closing

USD 27.75

Change

0.00 (0.00)%

Market Cap

USD 12.59B

Volume

0.69M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Perrigo Co PLC develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

+1.46 (+0.75%)

USD 83.17B
HLN Haleon plc

+0.03 (+0.28%)

USD 47.33B
TAK Takeda Pharmaceutical Co Ltd A..

+0.05 (+0.34%)

USD 46.60B
RDY Dr. Reddy’s Laboratories Ltd..

-0.15 (-0.19%)

USD 13.37B
CTLT Catalent Inc

+0.19 (+0.32%)

USD 10.83B
ELAN Elanco Animal Health

-0.24 (-1.65%)

USD 7.15B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.05 (+0.57%)

USD 2.73B
BHC Bausch Health Companies Inc

+0.18 (+2.57%)

USD 2.64B
CPHI China Pharma Holdings Inc

+0.03 (+16.49%)

USD 3.94M
YCBD cbdMD Inc

+0.03 (+5.28%)

USD 1.92M

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 9.49 % 0.00 %

+0.01 (+0.14%)

CAD 0.02B
ION Proshares S&P Global Core.. 3.98 % 0.00 %

+0.09 (+0.14%)

USD 2.24M
SETM:LSE HANetf ICAV - Sprott Ener.. 3.48 % 0.00 %

+0.01 (+0.14%)

USD 3.87M
SDIU:LSE Global X SuperDividend UC.. 1.20 % 0.00 %

+0.09 (+0.14%)

USD 0.24M
WSRD:CA Wealthsimple Developed Ma.. 1.10 % 0.00 %

+0.20 (+0.14%)

CAD 0.69B
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

+0.05 (+0.14%)

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
BLUM:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.77% 27% F 13% F
Dividend Return 1.72% 60% D- 40% F
Total Return -12.05% 27% F 14% F
Trailing 12 Months  
Capital Gain -17.26% 27% F 12% F
Dividend Return 2.46% 80% B- 37% F
Total Return -14.80% 27% F 12% F
Trailing 5 Years  
Capital Gain -51.06% 36% F 10% F
Dividend Return 8.38% 50% F 28% F
Total Return -42.67% 43% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain -13.00% 25% F 6% D-
Dividend Return -10.63% 25% F 6% D-
Total Return 2.36% 67% D+ 50% F
Risk Return Profile  
Volatility (Standard Deviation) 8.10% 100% F 82% B
Risk Adjusted Return -131.20% 6% D- N/A F
Market Capitalization 12.59B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector